Pfizer and BioNTech Doze First Participants in the U.S. As Part of Global COVID-19 MRNA Vaccine Development Program

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of …

Read MorePfizer and BioNTech Doze First Participants in the U.S. As Part of Global COVID-19 MRNA Vaccine Development Program

Adjuvance on forefront of COVID-19 vaccine battle

By Macy Meyer at klkntv.com

Adjuvance is developing a component that will strengthen a vaccine and prolong its dosage.

Tucked away in one of the many labs on Nebraska’s Innovation Campus lays the company Adjuvance. At the beginning of the year they were asked by the National Institute of Health to join in on the global race to fight COVID–19. Four months later they’re making strides. Read more